A Study of an Investigational Drug for Focal Segmental Glomerulosclerosis (FSGS)
Dr. Gahl and his team at the National Human Genome Research Institute are seeking volunteers aged 18 and older with primary FSGS to participate in a research study on the effects of an experimental drug, ManNAc, on this disease. The study aims to assess the long-term safety and tolerability of ManNAc and determine whether it can reduce protein in the urine of people with FSGS.